ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

COG.GB Cambridge Cognition Holdings PLC

54.50
0.00 (0.00%)
28 Mar 2024 - Closed
Realtime Data
Share Name Share Symbol Market Type Share ISIN Share Description
Cambridge Cognition Holdings PLC AQSE:COG.GB Aquis Stock Exchange Ordinary Share GB00B8DV9647
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 54.50 51.00 58.00 54.50 54.50 54.50 0.00 06:57:51
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Cambridge Cognition Holdings PLC Contract Win (6495E)

20/07/2016 7:00am

UK Regulatory


Cambridge Cognition (AQSE:COG.GB)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Cambridge Cognition Charts.

TIDMCOG

RNS Number : 6495E

Cambridge Cognition Holdings PLC

20 July 2016

20 July 2016

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

GBP0.5m contract win for Research business

The neuroscience company Cambridge Cognition Holdings PLC (Cambridge, UK - LSE: COG), which develops and markets near patient technologies for cognitive assessment, today announced that it has secured its largest contract to date for the CANTAB Connect Research(R) product, which is marketed for use in research projects by academic and small biotechnology research groups ("the Contract").

Worth an estimated GBP0.5 million, the Contract is the Company's first with an international biobank and the highest recorded sale of its research software. Biobanks amass large amounts of data and biological samples and catalogue them according to genetic, biological, environmental and other traits. These data and samples are then made available for researchers to support medical research in many fields. There are over 300 biobanks globally and the addition of neurological health data generated using Cambridge Cognition products will help to progress research into prevalent health issues, now and in the future.

The Contract allows for unlimited assessments to be conducted using the Company's proprietary touchscreen cognitive tests based on over 30 years of peer-reviewed science. The software will generate data that will be used for medical research to assess mental health in a general population over the next five years.

Dr Steven Powell, Chief Executive Officer, Cambridge Cognition: "Biobanks play a crucial role in biomedical research, enabling pharmaceutical companies to translate research into better treatments. We are therefore excited to be working in partnership with biobanks internationally, helping them advance drug development by enhancing their research capabilities."

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

Enquiries

 
 Cambridge Cognition Holdings PLC 
 Steven Powell, Chief Executive         Tel: 01223 810 
  Officer                                700 
  Noah Konig, Director of Product        press@camcog.com 
  Marketing and Communications 
 
 finnCap Ltd (NOMAD and Joint Broker)   Tel: 020 7220 
                                         0500 
 Geoff Nash / Simon Hicks               (Corporate Finance) 
 Alice Lane                             (Corporate Broking) 
 Hybridan LLP (Joint Broker)            Tel: 020 3764 
                                         2341 
  Claire Noyce                           (Corporate Broking) 
 

Notes to editors

About Cambridge Cognition

Cambridge Cognition is an international neuroscience company which develops and markets near patient cognitive assessment products to improve the understanding, diagnosis and treatment of neurological and psychiatric disorders.

For over 30 years the company's patented technology has advanced the assessment of cognition to accelerate the development of safe and effective treatments, improve patient outcomes and monitor and manage cognitive health throughout life.

Partners include the world's leading biotechnology and pharmaceutical companies; leading academic institutions; and public-private healthcare providers.

www.cambridgecognition.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

CNTUKSVRNRABAAR

(END) Dow Jones Newswires

July 20, 2016 02:00 ET (06:00 GMT)

1 Year Cambridge Cognition Chart

1 Year Cambridge Cognition Chart

1 Month Cambridge Cognition Chart

1 Month Cambridge Cognition Chart

Your Recent History

Delayed Upgrade Clock